Monday, May 29, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from Apellis
Steering Committee Chair
Professor and Chair
Department of Ophthalmology and Optometry
Medical Director
Christian Doppler Laboratory for Ophthalmic Image Analysis (OPTIMA)
Medical University Vienna
Vienna, Austria
Deputy Director
Centre for Eye Research Australia
Professor of Surgery (Ophthalmology)
University of Melbourne
Melbourne, Australia
Chairman
Department of Ophthalmology
University of Bonn
Bonn, Germany
Director
Institut de la Màcula and Barcelona Macula Foundation
Barcelona, Spain
Professor of Ophthalmology
Université de Paris
Head of Ophthalmology
Lariboisière
St Louis and Rothschild Foundation Hospital
Paris, France
Professor of Ophthalmology
Institute of Ophthalmology
University College London
Consultant Ophthalmologist
Moorfields Eye Hospital
London, United Kingdom
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Apellis
Research funding from: Genentech; Kodiak; Novartis AG; RetInSight; Roche
Patent beneficiary of: RetInSight
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Apellis; Bayer; Novartis; Roche/Genentech
Served as a speaker or a member of a speakers bureau for: Apellis; Bayer; Novartis; Roche/Genentech
Has disclosed the following relevant financial relationships:
Consultant or advisor for: Acucela; Apellis; Bayer; Bioeq/Formycon; Boehringer Ingelheim; Geuder; Grayburg; Gyroscope; Heidelberg Engineering; Iveric Bio; Kanghong; LinBioscience; Novartis; Oxurion; Pixium Vision; Roche/Genentech; Stealth BioTherapeutics; Zeiss
Research funding from: Acucela; Allergan; Bayer; Bioeq/Formycon; Center Vue; Heidelberg Engineering; Kanghong; Night Star; Novartis; Optos; Pixium Vision; Roche/Genentech; Zeis
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Apellis; Cellcure; Ionis Pharmaceuticals; Iveric Bio; Kodiak; Lineage Cell Therapeutics; Maculogix; Novartis; Reneuron; Roche
Served as a speaker or a member of a speakers bureau for: Alexion; Apellis; Cellcure; Ionis Pharmaceuticals; Iveric Bio; Lineage Cell Therapeutics; Maculogix; Novartis; Reneuron
Received grants for clinical research from: Apellis; Ionis Pharmaceuticals; Iveric Bio; Kodiak; Novartis; Reneuron; Roche
Owns stock, stock options, or bonds from: Iveric Bio; Notalvision
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Alcon; Allergan; Apellis; Bayer; Genentech; Iveric Bio; KHB; Novartis; Oculis; Roche; Thea
Served as a speaker or a member of a speakers bureau for: AbbVie; Alcon; Allergan; Bayer; Genentech; Novartis; Roche
Received grants for clinical research from: AbbVie; Allergan; Bayer; Novartis
Other: Oculis - private stock
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergan; Apellis; Bayer; Roche/Genentech; Heidelberg; Iveric Bio; Kanghong; Novartis
Served as a speaker or a member of a speakers bureau for: Bayer; Novartis
Received grants for clinical research from: Bayer; Novartis
Owns stock, stock options, or bonds from: Oculogics Vision AI
